Abstract: A method of inactivating a lipid virus in a protein carrier by contacting said virus for an abbreviated period of time and ambient temperature with a halohydrocarbon solvent or treating agent, preferably chloroform, in an amount of 5% v/v to 50% v/v. Preferred lipid viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH).

Abstract: A centrifugal blood component separator with a spiral helically inclined rotor chamber. The apparatus uses continuous blood flow-through without rotating seals. At the lower end of the helical rotor chamber there are terminals for blood input and packed red blood cell output, whereas at the higher end there is a terminal for plasma. Intermediate outlet terminals may be provided for white blood cells and platelets.

Abstract: A print-washing tank with generally rectangular spirally-looped pipes in parallel vertical arrays, fed by a horizontal input conduit in the upper portion of the tank, the arms of the pipes having holes to spray photographic prints on both sides with jets of water, the prints being supported between the vertical spray loops, using either wire baskets or being supported directly in the narrow vertical spaces between the spirally looped pipes. A drain pipe array is provided at the bottom of the tank, having a plurality of widely spaced intake ports and leading to a vertical siphon exit conduit near the back wall of the tank and which may be either inside the tank or may be located externally. The top loop of the siphon drain system is located slightly below the level of the water input pipe.

Abstract: This invention relates to a method of inactivating a non-A, non-B hepatitis agent by means of formalin utilized in extended treatment. The range of formalin treatment utilizes a concentration of 1:1,000-1:10,000, preferred 1:1,000, and the duration of treatment is from 24-120 hours at any temperature with a preferred 96 hours (4 days) at 37.degree..+-.4.degree. C. This formalin-treated or otherwise inactivated agent, or portions of the agent, may be later used to produce a vaccine against non-A, non-B hepatitis.

Abstract: A multi-step method of producing the compound methanesulfon-m-anisidide, 4'-(9-acridinylamino)-, acetate (VII), which may be in free base form and designated NSC 249992, also known as AMSA. This compound is produced by an elegant process from a starting material, 4-butyrylamino-3-methoxy-nitrobenzene, which is later transformed to methanesulfon-m-anisidide, 4'-amino- (IV) and is coupled or joined to 9-chloro-acridine, producing the chloride salt which is later converted to the acetate.

Abstract: A portable high-speed neutron spectrometer consisting of an organic scintillator, a true zero-crossing pulse shape discriminator, a 1 MHz conversion-rate multichannel analyzer, an 8-bit microcomputer, and appropriate displays. The device can be used to measure neutron energy spectra and kerma rate in intense n-.gamma. radiation fields in which the neutron energy is from 0.5 to 15 MeV.

Abstract: An electrode for implantation in the heart to control atrio-ventricular block by artificial pacemaker including plural electrically conductive wires grouped in a bundle with spring metal arcuate prongs formed on one end thereof. A sheath is provided to compress the prongs for insertion of the electrode through a cannula to place the electrode against the heart. The electrode is implanted in the heart by advancing the prongs through the pericardium into the myocardium.

Abstract: Blood-contacting surfaces of artificial implant devices which have been flocked with fibers of a blood-compatible polymeric material to promote formation of a stable and viable biological lining when the device has been implanted in a living body, are treated to strengthen the bonds between the fibers and the substrate surface and to interlock the fibers with each other so as to substantially reduce the possibility of fiber separation and release from the substrate surface into the blood stream. The treatment is effected by applying to the flocked surface a dilute solution of an adhesive material in a solvent therefor, the content of the adhesive material in the treating solution being controlled so as to be sufficient to coat the fibers only at their points of contact with each other and with the substrate surface.

Abstract: A process and resulting product for producing large unilamellar phosphatidylserine vesicles (LUV) in the diameter of about 2,000-12,000 A which may additionally encapsulate a drug. The large vesicles are prepared from an initial phosphatidylserine aqueous solution which is subjected to ultrasound or sonicated which produces small unilamellar vesicles (SUV) in the diameter range of 200-500 A. After the addition of calcium ion (Ca.sup.2+) in the molar concentration of about 1-10 mM (threshold 1-2 mM) and incubating for 30-60 minutes at room temperature above 10.degree. C and preferably 37.degree. C, intermediate cochleate lipid cylinders form. Finally, addition of a calcium chelating agent such as EDTA or EGTA to these cochleate cylinders produces by fusion the desired large closed spherical unilamellar vesicles (LUV). The intermediate cochleate form appears specific to the phospholipid serine utilized and to the calcium ion (Ca.sup.2+) incubating agent.

Abstract: An affinity chromatography method for the separation and pruification of two active forms of urokinase from a crude urokinase preparation. The method employs an extracting agent of agmatine covalently coupled to the surface of a water-insoluble solid support material such as agarose, and three separate specific buffer solutions. A low ionic strength buffer, such as 0.01 molar sodium phosphate buffer, pH 6.0-9.0, is used in preparing the loading solution and for washing the extracting agent. A slightly higher ionic strength buffer, such as 0.02 molar sodium phosphate buffer, pH 6.0-9.0, is used as a first eluant for eluting from the extracting agent a first active form of urokinase which is characterized by a molecular weight of approximately 33,400 and a specific activity of approximately 226,000 CTA units/mg protein. A still higher ionic strength buffer with added salt, such as 0.1 molar sodium phosphate -- 0.4 molar sodium chloride buffer, pH 5.0-8.

Abstract: A nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-l-lysine and carboxymethylcellulose, and injectable preparations thereof in a pharmaceutically acceptable aqueous carrier such as saline solution. When administered to a primate host, the complex is effective in inducing the synthesis in such host of antiviral levels of interferon.

Abstract: A process of producing angular alicylated polycyclides by electrochemical annelation wherein a biphenyl compound containing an alkyl group is oxidized at the anode in an electrolyte to form the corresponding dieone.

Abstract: A facile process for the production of Ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] which comprises reacting 2,4-bis-trimethylsilyl uracil with 2-chlorotetrahydrofuran to produce 1-tetrahydro-2-furanyluracil at low temperatures in a dry non-aqueous solvent, e.g. a halogenated hydrocarbon solvent such as methylene chloride. Subsequently the desired final product is produced by direct fluorination of the uracil ring as the last step utilizing a fluorinating agent such as trifluoromethylhypofluorite. This step is conducted in the cold and again in the presence of a halogenated hydrocarbon solvent such as chloroform. Ftorafur has been utilized as a pyrimidine analog for the management of carcinoma in the breast and large intestine and with less side effects than 5-fluorouracil (5-FU).